Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck Buys Animal Health Company Antelliq

Merck & Co. is paying about $2.4 billion to acquire all outstanding shares of Antelliq Group, and is also assuming the digital technology company’s debt of $1.3 billion.

Read More »

Amgen Terminates $540 Million Deal with Advaxis

Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.

Read More »

Akorn shares fall after Delaware court rules in favor of Fresenius

The Delaware Supreme Court said in a court filing that Germany’s Fresenius SE properly terminated the company’s merger agreement with Akorn Inc., sending shares of the U.S generic drugmaker down more than 30 percent.

Read More »

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.

Read More »

Despite Opposition, Takeda Shareholders Approve Shire Acquisition

Shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Ireland’s Shire for about $58 billion.

Read More »

Nestle raises stake in food allergy drug developer

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.

Read More »

Illumina to buy rival Pacific Biosciences

Gene sequencing company Illumina Inc. plans to buy Pacific Biosciences of California Inc. in an all-cash deal valued at $1.2 billion.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Eli Lilly, Dicerna Reach RNAi Therapies Deal

Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.

Read More »

Novo Nordisk hires AstraZeneca executive

Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom